What Gain Therapeutics, Inc. does.

We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.

GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people with Parkinson’s disease with or without a GBA1 mutation.

We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287. In preclinical models of GBA1 and idiopathic Parkinson’s disease, GT-02287 has been shown to restore glucocerebrosidase, or GCase, function in the lysosome, improve mitochondrial health, reduce toxic lipid substrates and toxic forms of alpha-synuclein, reduce neuroinflammation, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function and improve cognition, and reduce plasma-based neurodegeneration maker, neurofilament light chain (NfL) back to the level of healthy animals.

Revenue and profit, by fiscal year.

More on GANX.

• Gain Therapeutics, Inc. summary
• Gain Therapeutics, Inc. financial statements
• Gain Therapeutics, Inc. key metrics
• Gain Therapeutics, Inc. health scores and style box
• Gain Therapeutics, Inc. earnings
• Gain Therapeutics, Inc. dividends
• Gain Therapeutics, Inc. valuation
• Gain Therapeutics, Inc. ownership and insiders
• Gain Therapeutics, Inc. peers

Figures from Gain Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.